阅读说明：本技术 用于治疗过早老化疾病的方法和组合物 (Methods and compositions for treating premature aging diseases ) 是由 E.马科图利 D.阿尔米纳纳 R.德林格尔 M.莫里斯 于 2018-10-05 设计创作，主要内容包括：本文提供了涉及通过给予受试者(例如,口服给予受试者)包含烟酰胺核苷和/或紫檀芪的组合物,在受试者中治疗和/或预防过早老化疾病和/或早老样综合征的方法和组合物。(Provided herein are methods and compositions relating to the treatment and/or prevention of a premature aging disease and/or a presenile-like syndrome in a subject by administering (e.g., orally administering to the subject) a composition comprising nicotinamide riboside and/or pterostilbene.)

1. A method of treating or preventing a disease or disorder associated with premature aging in a subject comprising administering to the subject a composition comprising nicotinamide riboside.

2. The method of claim 1, wherein the composition further comprises pterostilbene.

3. The method of claim 1 or 2, wherein the disease or disorder associated with premature aging is Wolner Syndrome (WS), Blume Syndrome (BS), Ro-Tourette syndrome (RTS), Kekahn syndrome (CS), Xeroderma Pigmentosum (XP), Hair hypotony dystrophy (TTD), Combined xeroderma pigmentosum-Kekahn syndrome (XP-CS), Hair hypotony dystrophy or Hao-Giesei's progeria syndrome (HGPS).

4. The method of claim 3, wherein the disease or condition associated with premature aging is Heya-Gilbert's progeria syndrome (HGPS).

5. The method of claim 3, wherein the disease or disorder associated with premature aging is Warner's Syndrome (WS).

6. The method of claim 3, wherein the disease or disorder associated with premature aging is Cokahn's Syndrome (CS).

7. The method of claim 1 or 2, wherein the disease or disorder associated with premature aging is a disease or disorder caused by a mutation in a gene encoding a lamin protein.

8. The method of claim 7, wherein the lamin is lamin A.

9. The method of claim 7, wherein the lamin is lamin C.

10. The method of claim 1 or 2, wherein the disease or disorder associated with premature aging is a disease or disorder caused by a mutation in a gene encoding a DNA repair protein.

11. The method of claim 10, wherein the DNA repair protein is a RecQ protein-like helicase (RECQL) or Nucleotide Excision Repair (NER) protein.

12. A method of treating or preventing presenilinoid syndrome in a subject comprising administering to the subject a composition comprising nicotinamide riboside.

13. The method of claim 12, wherein the composition further comprises pterostilbene.

14. The method of claim 12 or 13, wherein the progeria-like syndrome is Warner Syndrome (WS), rotken syndrome (RTS), Cockayne Syndrome (CS), low hair sulfur dystrophy (TTD), combined xeroderma pigmentosum-cockayne syndrome (XP-CS), low hair sulfur dystrophy or heuchi-gipsy-progeria syndrome (HGPS).

15. The method of claim 12 or 13, wherein the presenilinoid syndrome is associated with or caused by a mutation in a gene encoding a lamin protein.

16. The method of claim 15, wherein the lamin is lamin a or lamin C.

17. The method of claim 12 or 13, wherein the presenilinoid syndrome is associated with or caused by a mutation in a gene encoding a DNA repair protein.

18. The method of claim 17, wherein the DNA repair protein is a RecQ protein-like helicase (RECQL) or Nucleotide Excision Repair (NER) protein.

19. A method of treating or preventing symptoms of a disease or disorder associated with premature aging in a subject in need thereof, comprising administering to the subject a composition comprising nicotinamide riboside.

20. The method of claim 19, wherein the composition further comprises pterostilbene.

21. The method of any one of claims 1-20, wherein administering the composition comprises administering one or more doses of the composition.

22. The method of claim 21, wherein each dose of said composition comprises at least 200mg nicotinamide riboside.

23. The method of claim 21, wherein each dose of said composition comprises at least 250mg nicotinamide riboside.

24. The method of claim 21, wherein each dose of said composition comprises at least 300mg nicotinamide riboside.

25. The method of claim 21, wherein each dose of said composition comprises at least 350 mg nicotinamide riboside.

26. The method of claim 21, wherein each dose of said composition comprises at least 400 mg nicotinamide riboside.

27. The method of claim 21, wherein each dose of said composition comprises at least 450 mg nicotinamide riboside.

28. The method of claim 21, wherein each dose of said composition comprises at least 500 mg nicotinamide riboside.

29. The method of claim 21, wherein each dose of said composition comprises at least 550 mg nicotinamide riboside.

30. The method of any one of claims 21-29, wherein each dose of the composition comprises at least 15mg of pterostilbene.

31. The method of any one of claims 21-29, wherein each dose of the composition comprises at least 25mg of pterostilbene.

32. The method of any one of claims 21-29, wherein each dose of the composition comprises at least 50mg of pterostilbene.

33. The method of any one of claims 21-29, wherein each dose of the composition comprises at least 75mg of pterostilbene.

34. The method of any one of claims 21-29, wherein each dose of the composition comprises at least 100mg of pterostilbene.

35. The method of any one of claims 21-29, wherein each dose of the composition comprises at least 125 mg of pterostilbene.

36. The method of any one of claims 21-29, wherein each dose of the composition comprises at least 150 mg of pterostilbene.

37. The method of any one of claims 21-36, wherein two or more doses of the composition are administered.

38. The method of any one of claims 21-37, wherein thirty or more doses of the composition are administered.

39. The method of any one of claims 21-38, wherein fifty or more doses of the composition are administered.

40. The method of any one of claims 21-39, wherein one hundred or more doses of the composition are administered.

41. The method of any one of claims 21-40, wherein a dose of the composition is administered at least once a week.

42. The method of any one of claims 21-40, wherein the dose is administered at least twice a week.

43. The method of any one of claims 21-40, wherein the dose is administered at least three times a week.

44. The method of any one of claims 21-40, wherein the dose is administered at least once a day.

45. The method of any one of claims 21-40, wherein the dose is administered at least twice a day.

46. The method of any one of claims 41-45, wherein the dose is administered for at least 7 days.

47. The method of any one of claims 41-45, wherein the dose is administered for at least 30 days.

48. The method of any one of claims 41-45, wherein the dose is administered for at least 60 days.

49. The method of any one of claims 41-45, wherein the dose is administered for at least 90 days.

50. The method of any one of claims 1-49, wherein the composition is formulated as a pill, tablet, or capsule.

51. The method of any one of claims 1-50, wherein the composition is administered orally.

52. The method of any one of claims 1-51, wherein the composition is self-administered.